VEGF and PEDF in Patients With Myopic Choroidal Neovascularization

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia

NCT00967850

Myopia Choroidal Neovascularization

COMPLETED PHASE3

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

NCT01025934

Proliferative Diabetic Retinopathy

COMPLETED PHASE4

Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

NCT00370786

Choroidal Neovascularization

COMPLETED PHASE3

The Treatment Burden of Myopic Choroidal Neovascularization

NCT07009574

Myopic Choroidal Neovascularisation Anti-VEGF Treatment Burden

NOT_YET_RECRUITING

Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia

NCT01716026

Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopic Choroidal Neovascularization VEGF Aqueous Level PEDF Aqueous Level

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Myopic Choroidal Neovascularization patients

No interventions assigned to this group

Control patients undergoing cataract surgery

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pathologic myopia, defined as spherical equivalent \>6 diopters and axial length \>26 mm
* posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent);
* fluorescein angiography, indocyanine green angiography and optical coherence tomography detection of the subfoveal or juxtafoveal choroidal neovascularization
* clear ocular media;

Exclusion Criteria

* previous treatment for choroidal neovascularization, including the previous intravitreal drug injection or PDT
* presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion
* history of recent myocardial infarction or other thromboembolic events
* ongoing uncontrolled hypertension or glaucoma
* refractive media opacities
* previous eye surgery

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No